Loading…
Loading…
LMDX (LumiraDx Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- AssureCKD, a Canadian medical device company developing point-of-care solutions for chronic kidney disease (CKD) screening and diagnosis, today announced the appointment of Dr. Aman Khan as Chief Technology Officer, effective April 13, 2026. Dr. Khan brings more than 30 years of experience in diagnostics and medical technology, with a proven track record of leading platform development from concept through to global commercialization.
PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. “We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and.
LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards.
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche.
Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares.
When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.
No recent filings indexed.